Lenacapavir, injectable twice a year, is developed by the US-based biopharmaceutical company Gilead Sciences, Inc. as a pre-exposure prophylaxis (PrEP) drug. These drugs prevent the spread of infection in people not yet exposed to the disease-causing agent
Subscribe to get the latest posts to your email.
Prime Minister Narendra Modi begins his two-day (July 8 to 9) visit to Moscow. He is in Russia at the invitation of Vladimir Putin to […]
The time has come for us to awaken a public consciousness where respect for women is increased and no woman feels unsafe, said President Droupadi […]
Currently, Tata Electronics is the only Indian supplier working with Apple, producing enclosures for iPhones. However, Aequs has also reportedly begun trial production of MacBook […]